IBIO vs REGN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. IBIO and REGN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined IBIO and REGN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

iBio, Inc. is a clinical-stage biotechnology company that applies artificial intelligence and proprietary 3D modeling of subdominant and conformational epitopes to discover antibodies that other approaches have struggled to develop. Its focus is obesity, cardiometabolic, and cardiopulmonary diseases, an area drawing intense interest as GLP-1 weight-loss drugs create demand for therapies that preserve lean muscle mass. The lead program, IBIO-600, is a long-acting anti-myostatin antibody engineered for infrequent dosing that iBio positions as potentially best-in-class; the company dosed the first participant in a Phase 1 trial in Australia in 2026, becoming a clinical-stage company. A second program, IBIO-610, is an activin E antibody that reduced visceral and total fat in obese non-human primate studies.

Full IBIO guide

Regeneron makes money primarily through two large franchises. Dupixent, an anti-inflammatory antibody used for eczema, asthma, COPD, and other conditions, is developed and commercialized in collaboration with Sanofi, and Regeneron records its share through Sanofi collaboration revenue (about $1.6 billion in Q1 2026, up roughly 36%). Eylea and the higher-dose Eylea HD treat retinal diseases such as wet age-related macular degeneration and diabetic eye disease, generating combined U.S. net product sales of about $941 million in Q1 2026, with Eylea HD now roughly half of that mix. Libtayo in oncology and a pipeline of nearly 50 clinical candidates round out the revenue base.

Full REGN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• IBIO drivers: AI antibody-discovery platform; Obesity and muscle-preservation wave.
• REGN drivers: Dupixent keeps compounding; A deep, diversified pipeline.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is that iBio is a speculative, essentially pre-revenue micro-cap whose survival depends on continually raising money. For REGN, the clearest risk is Eylea biosimilar erosion.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick IBIO if you believe its drivers more; REGN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the IBIO and REGN guides.

IBIO. Figures are approximate and tied to the asOf date; verify live numbers before acting. For a pre-revenue clinical-stage biotech, traditional valuation multiples such as P/E are not meaningful because there are no sustained earnings. What matters far more is cash runway versus burn rate, the pace and results of clinical trials, and how much dilution future funding requires. Treat any single quarter's cash figure and any analyst target as a snapshot, not a stable anchor.

REGN. Figures are approximate and tied to the asOf date; verify current numbers with a live quote before acting. Regeneron reported about 19% revenue growth and adjusted EPS of roughly $9.47 in Q1 2026, beating estimates, and authorized an additional $3 billion buyback. The mid-teens P/E reflects the market weighing strong Dupixent growth against expected Eylea biosimilar erosion.

Headline figures (approximate, Jul 2026): IBIO shows revenue Essentially none from products; iBio is a clinical-stage biotech with only minimal reported revenue, so standard sales-based metrics do not apply, net loss Consistently loss-making, as expected for a company investing in R&D ahead of any approved product; losses are funded by capital raises, cash position / runway Roughly $74.8 million in cash, equivalents, and debt securities as of March 31, 2026; management has said financings extend the runway into fiscal 2028, market cap (micro-cap) In the tens of millions of dollars in mid-2026, placing IBIO firmly in micro-cap territory with the volatility that implies; REGN shows total revenue (ttm, approx) ~$14 billion, q1 2026 total revenue ~$3.6 billion (up ~19% YoY), dupixent global net sales (q1 2026) ~$4.9 billion (up ~31%), eylea + eylea hd u.s. net sales (q1 2026) ~$941 million combined.

IBIO and REGN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined IBIO and REGN exposure against your real portfolio. It is not an investment adviser.